Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
ABCB1 overexpression
Cancer:
Ovarian Cancer
Drug:
lapatinib
(
EGFR inhibitor
,
HER2 inhibitor
) +
Pozenveo (poziotinib)
(
HER2 inhibitor
,
HER4 inhibitor
,
pan-EGFR inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
PLoS One
Title:
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
Published date:
08/04/2021
Excerpt:
...lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro.
DOI:
10.1371/journal.pone.0254205
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.